IceCure Medical Receives 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance
ICCM is trading near its 52-week low of $0.223 (11% above the low).
Summary
IceCure Medical received a 180-day extension from Nasdaq to regain compliance with the minimum bid price rule, avoiding immediate delisting but signaling ongoing challenges.
Key Events · Corporate Governance and Compliance · ICCM
-
Nasdaq Compliance Extension Granted
IceCure Medical received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, extending the deadline to November 9, 2026.
-
Previous Non-Compliance
The company failed to regain compliance during the initial 180-day period, which ended on May 11, 2026, after first being notified on November 12, 2025.
-
Potential Reverse Share Split
IceCure Medical indicated its intention to cure the deficiency, potentially by effecting a reverse share split if necessary.
-
No Immediate Delisting
The notification has no immediate effect on the listing or trading of the company's ordinary shares on the Nasdaq Capital Market.
Analysis · ICCM · Industrial Applications And Services
IceCure Medical has been granted a critical 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement, pushing the deadline to November 9, 2026. This extension provides a temporary reprieve from potential delisting, which would severely impact the company's visibility and liquidity, especially for a micro-cap company already facing a 'going concern' warning. The company's stated intention to potentially effect a reverse share split to cure the deficiency highlights the severity of the situation and could be viewed negatively by investors.
At the time of this filing, ICCM was trading at $0.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $0.22 to $1.40. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.